Baseline characteristics and comparison between groups defined by LCBI ≥ median, MaxLCBI4mm ≥400 and MaxPB ≥70%
| Non-culprit LCBI | Non-culprit MaxLCBI4mm | Non-culprit MaxPB | |||||||
| <65 (n=72) | ≥65 (n=72) | P value | <400 (n=108) | ≥400 (n=36) | P value | <70 (n=131) | ≥70 (n=13) | P value | |
| Age | 66.9 (11.58) | 66.2 (11.7) | 0.81 | 66.7 (11.9) | 66.1 (10.9) | 0.76 | 66.5 (11.8) | 66.9 (9.3) | 0.93 |
| Male sex | 51 (70.8) | 51 (70.8) | 1.00 | 77 (71.3) | 25 (69.4) | 0.83 | 91 (69.5) | 11 (84.6) | 0.25 |
| Smoker | 13 (18.1) | 15 (20.8) | 0.62 | 21 (19.4) | 7 (19.4) | 1.0 | 25 (19.1) | 3 (23.1) | 0.73 |
| Hypertension | 45 (62.5) | 32 (44.4) | 0.03 | 58 (53.7) | 19 (52.8) | 0.92 | 71 (54.2) | 6 (46.2) | 0.58 |
| Diabetes | 14 (19.4) | 14 (19.4) | 1.00 | 18 (16.7) | 10 (27.8) | 0.15 | 25 (19.1) | 3 (23.1) | 0.73 |
| Previous MI | 21 (29.2) | 21 (29.2) | 1.00 | 33 (30.6) | 9 (25.0) | 0.53 | 37 (28.2) | 5 (38.5) | 0.44 |
| Previous TIA/Stroke | 6 (8.5) | 8 (11.1) | 0.59 | 10 (9.3) | 4 (11.1) | 0.76 | 14 (10.8) | 0 (0.0) | 0.21 |
| Medications at admission: | |||||||||
| Statin | 34 (47.2) | 32 (44.4) | 0.74 | 51 (47.2) | 15 (41.7) | 0.56 | 59 (45.0) | 7 (53.8) | 0.54 |
| ACEi | 18 (25.0) | 16 (22.2) | 0.70 | 29 (26.9) | 5 (13.9) | 0.11 | 31 (23.7) | 3 (23.1) | 0.96 |
| ARB | 15 (20.8) | 10 (13.9) | 0.27 | 20 (18.5) | 5 (13.9) | 0.53 | 22 (16.8) | 3 (23.1) | 0.57 |
| Ca blocker | 15 (20.8) | 11 (15.3) | 0.39 | 21 (19.4) | 5 (13.9) | 0.45 | 23 (17.6) | 3 (23.1) | 0.62 |
| Cholesterol total | 4.67 (1.35) | 4.64 (1.21) | 0.59 | 4.72 (1.3) | 4.44 (1.2) | 0.41 | 4.67 (1.29) | 4.55 (1.13) | 0.74 |
| Cholesterol HDL | 1.25 (0.38) | 1.17 (0.33) | 0.11 | 1.25 (0.38) | 1.09 (0.22) | 0.04 | 1.22 (0.37) | 1.08 (0.15) | 0.34 |
| Cholesterol LDL | 2.88 (1.22) | 2.91 (1.10) | 0.62 | 2.94 (1.19) | 2.76 (1.07) | 0.56 | 2.91 (1.18) | 2.81 (1.02) | 0.80 |
| Indication: | 0.93 | 0.55 | 0.14 | ||||||
| STEMI | 32 (44.4) | 31 (43.1) | NA | 48 (44.4) | 15 (41.7) | NA | 60 (45.8) | 3 (23.1) | NA |
| NSTEMI | 16 (22.2) | 19 (26.4) | NA | 23 (21.3) | 12 (33.3) | NA | 31 (23.7) | 4 (30.8) | NA |
| UAP | 11 (15.3) | 9 (12.5) | NA | 16 (14.8) | 4 (11.1) | NA | 19 (14.5) | 1 (7.7) | NA |
| SAP | 13 (16.7) | 13 (18.1) | NA | 21 (19.5) | 5 (13.9) | NA | 21 (16.0) | 5 (38.5) | NA |
ACEi, angetensin converting enzyme inhibitor; ARB, angiotensin II receptor blocker; Ca blocker, calcium channel blocker; HDL, high-density lipoprotein; LCBI, lipid core burden index; LDL, low-density lipoprotein; MI, myocardial infarction; MaxLCBI4mm, 4mm segment with maximum lipid core burden index; MaxPB, maximum plaque burden; NSTEMI, non-ST-elevation myocardial infarction; SAP, stable angina pectoris; STEMI, ST-elevation myocardial infarction; TIA, transitory ischaemic attack; UAP, unstable angina pectoris.